Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Collaborative research sheds light on new cancer stem cell therapies

30.01.2012
A collaborative anti-cancer research jointly conducted by The Hong Kong Polytechnic University (PolyU), Peking University Shenzhen Graduate School and Nevada Cancer Institute has led to the development of a novel class of chemical inhibitors that specifically target cancer cells with pluripotency.
This cutting-edge research has combined the effort of three research teams including one led by Dr Tao Ye (—tŸ·), Associate Professor of PolyUfs Department of Applied Biology and Chemical Technology. This breakthrough may help the selective removal of cancer stem cells and potentially provide a novel strategy to eradicate cancers.

Cancer is a major cause of human death in China and all around the world. It is difficult to treat cause of the existence of cancer initiating cells/cancer stem cells. Although they exist in very few in numbers, cancer stem cells (CSCs) can proliferate and self-renew, and are pluripotent and multipotent, which have the capability to differentiate into various more heterogeneous cancer cells that constitute the entire tumor mass. As stem cells, they are more resistant to most conventional cancer therapies such as chemotherapy or radiotherapy due to their differences in the cell cycle regulation and DNA repair processes.
They also act as the source for metastasis and recurring drug resistant cancers after conventional cancer therapy. Currently, there are no chemical inhibitors or other agents that can specifically and selectively target cancer stem cells. The development of compounds that target cancer stem cells is an unmet medical demand for the eradication of malignant cancers.

According to Dr Ye, the potential clinical applications of new LSD1 inhibitors include the following:

(1) They can be used to treat malignant germ cell tumors such as teratoma/teratocarcinomas, embryonic carcinomas, seminomas, choriocarcinomas, and tumors of yolk sac. These tumors are usually treated by surgery or cis-platinum, but after initial treatment, these tumors always become resistant to platinum drugs. So far, the LSD1 inhibitors are highly effective towards these pluriptont cancers with stem cell properties.

(2) The LSD1 inhibitors may also be used to remove teratomas/embryonic carcinomas during stem cell-based therapy. One major problem in stem/iPS cell-based therapy is the formation of embryonic carcinomas, teratomas, or teratocarcinomas by incomplete differentiation of ES/iPS cells in the organs of recipients. Because LSD1 selectively inhibit these pluripotent embryonic carcinomas, teratomas, or teratocarcinomas, LSD1 inhibitors may help ensure the successful application of stem cell-based therapy.

(3) More importantly, since teratomas/embryonic carcinomas are pluripotent cancer stem cells, researchers will probe whether cancer stem cells of other types of major organ-specific cancers such as breast, ovarian, lung, and brain cancers are sensitive to these LSD1 inhibitors. Further studies indicated that LSD1 inhibitors can also be used to inhibit many cancer stem cell-like cells such as breast and ovarian cancers.

A leading scientist in the field of chemical biology, Dr Tao Ye has obtained large amounts of funding from the Research Grants Council to carry out basic research. Since 2010, his research activities have culminated in the publication of 12 original research papers in top research journals with an impact factor greater than five.

Dr Tao Yefs anti-cancer drug discovery programme was also supported by the generous donation of Fong Shu Fook Tong Foundation and Joyce M. Kuok Foundation.

Wilfred Lai | Research asia research news
Further information:
http://www.polyu.edu.hk
http://www.nature.com/nchina/2012/120104/full/nchina.2012.1.html
http://www.researchsea.com

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>